FDA Clears Magstim Horizon Inspire TMS System For Multiple Indications

Magstim announced that the U.S. Food and Drug Administration (FDA) granted marketing clearance for its Horizon Inspire System transcranial magnetic stimulation (TMS) device. The system is approved as treatment for major depressive disorder (MDD), obsessive-compulsive disorder (OCD), and anxious depression.

The Inspire system includes a portable device with preset clinical workflows. Magstim’s air-cooled coil reduces downtime and eliminates additional cooling expenses. Users also have access to the system’s advanced data analytics tools to improve treatment efficacy.

Earlier in 2024, the FDA granted clearance to Magstim’s TMS technology, Horizon 3.0 with StimGuide Pro, which . . .